Costanza Bogani

Costanza Bogani

UNVERIFIED PROFILE

Are you Costanza Bogani?   Register this Author

Register author
Costanza Bogani

Costanza Bogani

Publications by authors named "Costanza Bogani"

Are you Costanza Bogani?   Register this Author

21Publications

314Reads

20Profile Views

Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.

Br J Haematol 2016 06 25;173(6):938-40. Epub 2015 Aug 25.

Laboratorio Congiunto per le Malattie Mieloproliferative, Università degli Studi di Firenze, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13644DOI Listing
June 2016

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Haematologica 2015 Jun 3;100(6):757-67. Epub 2015 Apr 3.

INSERM UMR-S1197, Paul Brousse Hospital, Paris-Sud University, Villejuif, France INSERM UMS33, Paul Brousse Hospital, Paris-Sud University, Villejuif, France French Intergroup on Myeloproliferative Neoplasms (FIM), France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.118497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450621PMC
June 2015

Preclinical models for drug selection in myeloproliferative neoplasms.

Curr Hematol Malig Rep 2013 Dec;8(4):317-24

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0182-1DOI Listing
December 2013

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.

J Cell Mol Med 2013 Nov 17;17(11):1385-96. Epub 2013 Nov 17.

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.12162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4117551PMC
November 2013

Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.

Cancer Res 2009 Sep 25;69(18):7235-42. Epub 2009 Aug 25.

Medical Oncology 2, Department of Oncology, Azienda Ospedaliero-Universitaria Careggi, Istituto Toscano Tumori, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-4315DOI Listing
September 2009

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

J Cell Mol Med 2009 Aug 11;13(8A):1437-50. Epub 2009 Jun 11.

UF di Ematologia, Dip. Area Critica Medico-Chirugica, Università di Firenze, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1582-4934.2009.00827.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828857PMC
August 2009

Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Cancer Epidemiol Biomarkers Prev 2009 Jul 16;18(7):2068-73. Epub 2009 Jun 16.

Unità Funzionale di Ematologia, Dipartimento di Area Critica, Università degli Studi di Firenze, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-09-0353DOI Listing
July 2009

Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds.

Blood 2005 Dec 18;106(13):4102-13. Epub 2005 Aug 18.

Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, Viale Regina Elena 299, 00161 Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2005-03-1060DOI Listing
December 2005